AI

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Pliant Therapeutics (NASDAQ: PLRX) reported its fourth quarter results on Thursday, with a GAAP loss per share of $0.72, missing analysts\’ expectations by $0.02. However, the company\’s revenue of $1.97 million, down 1.5% year-over-year, beat expectations by $0.8 million. Pliant Therapeutics is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing novel treatments […]

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue Read More »

Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Poseida Therapeutics, a biotechnology company focused on developing gene therapies for cancer and other genetic diseases, reported disappointing Q4 2022 results on Thursday. The company\’s Q4 GAAP earnings per share (EPS) came in at -$0.39, missing expectations by $0.56. Meanwhile, revenue for the quarter was $10.05 million, down 67.8% year-over-year and missing estimates by $21.7

Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS Read More »

Walgreens\’ $54M Contract with California to be Canceled Over Abortion Pill Access

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Walgreens Boots Alliance (NASDAQ: WBA) is set to lose a $54M contract with California following the company\’s decision not to sell abortion pills in certain states. The contract, which provides specialty prescription drugs primarily to the California Department of Corrections and Rehabilitation and its correctional healthcare system, is set to expire on April 30. In

Walgreens\’ $54M Contract with California to be Canceled Over Abortion Pill Access Read More »

Scroll to Top